NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
today that it has received a Notice of Allowance from the United
States Patent and Trademark Office (USPTO) for Seelos' application
number 16/460,046 titled: "TREATMENT OF PROTEIN AGGREGATION
MYOPATHIC AND NEURODEGENERATIVE DISEASES BY PARENTERAL
ADMINISTRATION OF TREHALOSE".
The allowed claims cover a method of using trehalose (SLS-005)
to treat several neurodegenerative conditions including
spinocerebellar ataxia (SCA), spinal and bulbar muscular atrophy
(SBMA), dentatomral-pailidoluyssan atrophy (DRPLA), Pick's disease,
corticobasaldegeneration (CBD), progressive supranuclear palsy
(PSP), and frontotemporal dementia.
About Trehalose
Trehalose is a low molecular weight disaccharide (0.342 kDa) that
crosses the blood brain barrier, stabilizes proteins, and
importantly activates autophagy which is the process that clears
material from cells. In several animal models of diseases,
associated with abnormal cellular protein aggregation or storage of
pathologic material, it has been shown to reduce aggregation of
misfolded proteins and reduce accumulation of pathologic material.
Trehalose activates autophagy through the activation of
Transcription Factor EB (TFEB), a key factor in lysosomal and
autophagy gene expression. Activation of TFEB is an emerging
therapeutic target for a number of diseases with pathologic
accumulation of storage material.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download
multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-receives-notice-of-allowance-for-an-additional-us-patent-for-trehalose-sls-005-301126928.html
SOURCE Seelos Therapeutics, Inc.